INTENSITY THERAPEUTICS, INC. Net Fee Amt
INTENSITY THERAPEUTICS, INC. (INTS) had Net Fee Amt of $101.38 as of 2026-07-08, per its S-8 filed 2026-07-08.
Financial Statements › Notes
ffd:NetFeeAmt · last filed 2026-07-08
- 2026-07-08: Net Fee Amt $101.38.
| Period end | Net Fee Amt |
|---|---|
| 2026-07-08 | $101.38 S-8 · filed 2026-07-08 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| BRAINSTORM CELL THERAPEUTICS INC. (BCLI) | United States | $0.013B | -1.05 |
| Pluri Inc. (PLUR) | $0.014B | ||
| IN8BIO, INC. (INAB) | United States | $0.012B | -0.76 |
| Senti Biosciences Holdings, Inc. (SNTI) | United States | $0.011B | -0.70 |
| Passage BIO, Inc. (PASG) | United States | $0.015B | -0.43 |
| DYADIC INTERNATIONAL INC (DYAI) | United States | $0.016B | |
| BioCardia, Inc. (BCDA) | United States | $0.016B | |
| TScan Therapeutics, Inc. (TCRX) | United States | $0.008B | -1.23 |
| CERO THERAPEUTICS HOLDINGS, INC. (CERO) | United States | $0.007B | |
| Jasper Therapeutics, Inc. (JSPR) | United States | $0.020B | -0.37 |